Price still isn’t right for Biogen’s blockbuster drug
HSE says Spinraza drug for SMA sufferers would cost €38 million over five years, as pharma giant clocks up global annual sales of $1.72 billion
Biogen’s Spinraza clocked up global sales of $1.72 billion for the company last year.
It is being reimbursed by numerous health systems across Europe - but to varying degrees.
The HSE told Biogen that it would not reimburse Spinraza at the price it was offering.
Subscribe from just 1€
Choose the subscription that is right for you
For the first month
€19.99 Monthly ThereafterSubscribe today
For the first year
€199.99 annually thereafterSubscribe today
For the first 90 days
€55.00 quarterly ThereafterSubscribe today
These offers are not available for current subscribers. Offers and pricing are subject to change without notice.
Terms & Conditions Apply